Risk group-based management of differentiated thyroid carcinoma.
A number of controversies exist in the treatment of differentiated thyroid carcinoma with respect to the extent of surgery, use of radioactive iodine and post-operative thyroxine suppression. Recent recognition of prognostic factors has helped to assign patients, based on their risk profile, as being at high risk of developing recurrence. This has facilitated the development of a selective approach to therapy, thus, avoiding unnecessary treatment and reducing morbidity without compromising treatment outcome. This review attempts to evaluate the current concepts of management of differentiated thyroid carcinoma in the light of these new developments.
Kuriakose
M A
MA
Department of Otolaryngology, New York University School of Medicine, New York 10016, USA.
Hicks
W L
WL
Loree
T R
TR
Yee
H
H
D018263:Adenocarcinoma, Follicular / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D000328:Adult; D017677:Age Distribution; D000368:Aged; D001707:Biopsy, Needle; D002291:Carcinoma, Papillary / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D017678:Sex Distribution; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*